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Highlights 
•Job/time constraints limit the engagement of patients with NAFLD in counseling programs. 
•Web- and group-based programs promote similar calorie/physical activity changes. 
•Surrogate markers indicate reduced fat in the liver and no changes in hepatic fibrosis. 
•Web counseling results in clinically significant weight loss in motivated patients. 
•Structured web-based program is as effective as group-counseling in selected patients with 
NAFLD. 
Background & Aims. Interventions aimed at lifestyle changes are pivotal for the treatment of non-
alcoholic fatty liver disease (NAFLD), and web-based programs might help remove barriers in both 
patients and therapists. 
Methods. In the period 2010–15, 716 consecutive NAFLD cases (mean age, 52; type 2 diabetes, 
33%) were treated in our Department with structured programs. The usual protocol included 
motivational interviewing and a group-based intervention (GBI), chaired by physicians, dietitians 
and psychologists (five weekly meetings, n = 438). Individuals who could not attend GBI entered a 
web-based intervention (WBI, n = 278) derived from GBI, with interactive games, learning tests, 
motivational tests, and mail contacts with the center. The primary outcome was weight loss ≥10%; 
secondary outcomes were alanine aminotransferase within normal limits, changes in lifestyle, 
weight, alanine aminotransferase, and surrogate markers of steatosis and fibrosis. 
Results. GBI and WBI cohorts had similar body mass index (mean, 33 kg/m2), with more males 
(67% vs. 45%), younger age, higher education, and more physical activity in the WBI group. The 
two-year attrition rate was higher in the WBI group. Healthy lifestyle changes were observed in 
both groups and body mass index decreased by almost two points; the 10% weight target was 
reached in 20% of WBI cases vs. 15% in GBI (not significant). In logistic regression analysis, after 
adjustment for confounders and attrition rates, WBI was not associated with a reduction of patients 
reaching short- and long-term 10% weight targets. Liver enzymes decreased in both groups, and 
normalized more frequently in WBI. Fatty liver index was reduced, whereas fibrosis remained 
stable (NAFLD fibrosis score) or similarly decreased (Fib-4). 
Conclusion. WBI is not less effective than common lifestyle programs, as measured by significant 
clinical outcomes associated with improved histological outcomes in NAFLD. eHealth programs 
may effectively contribute to NAFLD control. 
Lay summary 
In patients with non-alcoholic fatty liver disease, participation in structured lifestyle programs may 
be jeopardized by job and time constraints. A web-based intervention may be better suited for 
young, busy patients, and for those living far from liver units. The study shows that, following a 
structured motivational approach, a web-based, interactive intervention coupled with six-month 
face-to-face meetings is not inferior to a standard group-based intervention with respect to weight 
loss, adherence to healthy diet and habitual physical activity, normalization of liver enzymes, and 
stable surrogate markers of fibrosis. 
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Introduction 
The burden associated with non-alcoholic fatty liver disease (NAFLD) is becoming a major 
problem for health systems worldwide.1 As part of the metabolic syndrome, NAFLD prevalence is 
increasing in parallel with the epidemics of obesity and diabetes;2 although in most cases NAFLD 
remains a non-progressive disease, in some cases non-alcoholic steatohepatitis (NASH) and 
progressive fibrosis may occur, finally progressing to cirrhosis and hepatocellular carcinoma.3 Thus, 
the costs associated with liver disease of metabolic origin and its complications are likely to soon 
outweigh the costs of liver diseases of viral origin.4 
Several drugs are under investigation to stop NAFLD progression,5 but none have been approved so 
far by regulatory agencies. Like any non-communicable disease, lifestyle changes remain the 
cornerstone of NAFLD prevention and treatment, and are also the background treatment suggested 
by all clinical practice guidelines, including the recent European guidelines shared by the Liver, 
Diabetes and Obesity Societies.6 
Programs to promote lifestyle changes have been developed in the community, mainly in the area of 
obesity and diabetes, following the seminal Finnish Diabetes Prevention Study and U.S. Diabetes 
Prevention Program. Their effectiveness in promoting weight loss has been demonstrated on long-
term follow-up.7 Programs of cognitive-behavioral therapy have also been applied in NAFLD;8 
weight loss through healthy and restrictive diet, coupled with habitual physical activity, has been 
reported to reduce NAFLD progression in small pilot trials,9-11 and a large prospective intervention 
study confirmed that weight loss is associated with histologic improvement on repeated liver 
biopsy.12 Unfortunately, these programs require dedicated teams and support, which are rarely 
found in liver units.13 In addition, it may be difficult to engage asymptomatic, scarcely motivated 
patients with NAFLD in intensive lifestyle protocols, because of space and time constraints.14 
eHealth technology is a possible resource to promote behavior changes,15 thus reducing NAFLD 
progression. The possibility to educate, to counsel and to induce permanent changes in motivated 
and engaged patients with NAFLD via an internet-based approach would reduce attendance to busy 
liver units, sparing patients’ and physicians’ time, and would expand lifestyle intervention to a 
much larger community.13 
The present study was aimed at measuring the effectiveness of a web-based educational 
intervention aimed at lifestyle changes, including healthy diet and habitual physical activity, and 
weight loss in individuals with NAFLD. 
Materials and methods 
Patients 
The study involves individuals with ultrasonography-diagnosed NAFLD attending the Unit of 
Metabolic Diseases and Clinical Dietetics, University of Bologna, from January 2010 to December 
2015. During this period a web-based lifestyle modification program was set up, funded as part of 
the subproject FP7/2007-2013 FLIP (Fatty Liver – Inhibition to Progression), under grant 
agreement No. HEALTH-F2-2009-241762. The majority of cases were part of a NAFLD cohort 
attending our outpatient service, which serves as second-level center for obesity and diabetes. A few 
were specifically addressed to our center for a second opinion because of NAFLD diagnosed 
elsewhere. According to our procedures, all NAFLD cases are routinely invited to enter a group-
based lifestyle modification program following initial assessment, diagnostic procedures and 
motivational interviewing.16 The initial assessment includes routine biochemistry, the measurement 
of calorie intake by an in house developed questionnaire (Quanto Mangio Veramente? – How much 
do I really eat?)[17], [18] and of habitual physical activity by the International Physical Activity 
questionnaire.19 The program, in use in our unit since 2003,20 was initially devised for patients with 
obesity and or type 2 diabetes (T2DM), and has been partly adjusted in the course of the years to 
cover the few specific needs of patients with NAFLD (see below). Patients who agreed to treatment 
(n = 438) entered and completed the lifestyle modification program within three months (group-
based intervention – GBI). 
The web program was specifically designed for individuals who could not attend the standard 
program; these individuals (n = 278) were provided a user-id and a password to access web-based 
intervention (WBI), largely reproducing the protocol and the tools of GBI. The main reasons for 
preferring the web program were time or job constraints, preventing attendance during weekdays, or 
living far from the center; the reasons for favoring the group-based therapy were scarce ability with 
e-technology and more severe comorbidities, possibly requiring more frequent contact with 
therapists. 
The socio-demographic and clinical data of the entire NAFLD cohort are presented (Table 1). These 
groups do not include cases (<5%) who received individual, face-to-face education because of 
specific needs. After enrollment in either program, all patients attended the clinic for follow-up 
visits every six months, receiving reinforcement and treatment for comorbidities, but no specific 
therapy for their liver disease. Patients with T2DM received drugs with possible hepatic effects: 
metformin, 73.1%; pioglitazone, 4.6%; glucagon-like peptide-1 receptor agonists, 3.7%; insulin, 
3.2% (all, no differences between WBI and GBI). Surrogate markers of steatosis (Fatty Liver Index 
– FLI)21 and fibrosis (NAFLD fibrosis score – NFS,22 Fibrosis-4 Calculator – Fib-4)23 were tested at 
baseline and at 12- and 24-month follow-up. 
Table 1. Socio-demographic, clinical and biochemical characteristics of patients with NAFLD 
enrolled in the lifestyle intervention program. 
 
 
Total 
(n = 716) 
Web–treated 
(n = 278) 
Group–treated 
(n = 438) 
p 
value* 
Sex (Males,%) 53.5 (49.8–57.0) 66.9 (61.0–72.0) 45.0 (40.3–49.5) <0.001 
Age (years) 51.6 ± 12.8 46.0 ± 11.5 55.1 ± 12.3 <0.001 
Weight (kg) 94.5 ± 18.7 99.4 ± 20.8 91.4 ± 16.5 <0.001 
Height (cm) 168.1 ± 10.4 171.6 ± 10.2 165.9 ± 9.8 <0.001 
BMI (kg/m2) 33.4 ± 5.5 33.7 ± 6.0 33.2 ± 5.2 0.273 
 Obesity (%) 70.4 (66.9–73.6) 67.6 (61.7–72.7) 72.1 (67.7–76.0) 0.196 
Waist circumference (cm) 106.4 ± 12.2 107.6 ± 13.2 105.6 ± 11.5 0.033 
 Waist ≥102 (M), ≥88 (F) (%) 42.5 (38.8–46.0) 29.8 (24.8–35.3) 50.5 (45.7–55.0) <0.001 
Systolic pressure (mmHg) 132.2 ± 13.7 129.3 ± 13.3 134.0 ± 13.7 <0.001 
Diastolic pressure (mmHg) 84.9 ± 9.0 83.5 ± 8.8 85.8 ± 9.0 0.008 
Diabetes (%) 33.2 (29.8–36.7) 21.6 (17.0–26.6) 40.6 (36.0–45.2) <0.001 
Prediabetes (IFG/IGT,%) 8.5 (6.6–10.7) 7.2 (4.6–10.6) 9.4 (6.9–12.5) 0.339 
Education     
 Primary/secondary/vocational/ university 
(%) 1/23/50/26 1/10/48/41 1/32/51/16 <0.001 
Residence     
 Within the metropolitan area (%) 58.5 (54.8–62.0) 41.7 (35.9–47.4) 69.2 (64.6–73.2) <0.001 
Employment status (%)     
 Student/housewife/employed/self–
employed/retired (%) 2/8/60/18/12 3/2/67/25/3 1/12/56/13/18 <0.001 
Fasting biochemistry     
 Glucose (mg/dl) 112.0 ± 34.0 100.5 ± 25.0 119.6 ± 36.9 <0.001 
 Insulin (mU/L) 20.1 ± 13.2 20.6 ± 14.8 19.7 ± 11.8 0.410 
 HOMA-R (%) 5.32 ± 3.68 5.10 ± 3.99 5.48 ± 3.42 0.222 
 Glycosylated hemoglobin (%) 7.22 ± 3.08 6.23 ± 1.64 7.54 ± 3.35 0.002 
 AST (mU/ml) 34.9 ± 17.8 31.9 ± 17.4 36.8 ± 17.9 <0.001 
 ALT (mU/ml) 55.2 ± 32.8 48.8 ± 28.8 59.3 ± 34.5 <0.001 
  Normal ALT (%) 14.2 (11.8–16.9) 18.3 (14.1–23.1) 11.6 (8.9–14.9) 0.016 
 GGT (mU/ml) 62.5 ± 59.8 53.3 ± 55.0 57.4 ± 40.4 0.257 
 Total cholesterol (mg/dl) 212.2 ± 42.5 205.0 ± 42.0 216.8 ± 42.2 <0.001 
 HDL–cholesterol (mg/dl) 46.4 ± 11.1 45.5 ± 10.6 47.0 ± 11.4 0.070 
 Triglycerides (mg/dl) 181.7 ± 117.2 165.1 ± 141.8 192.2 ± 97.2 0.003 
 LDL–cholesterol (mg/dl) 132.3 ± 38.0 129.7 ± 37.5 133.9 ± 38.4 0.150 
Surrogate markers     
 Fatty liver index (%) 82.3 ± 17.2 81.0 ± 17.5 83.1 ± 17.0 0.107 
  FLI ≥60% (%) 88.5 (85.9–90.6) 87.8 (83.2–91.0) 89.0 (85.6–91.5) 0.849 
Fib-4 score 1.22 ± 0.61 1.00 ± 0.46 1.36 ± 0.64 <0.001 
 
 
Total 
(n = 716) 
Web–treated 
(n = 278) 
Group–treated 
(n = 438) 
p 
value* 
 Fib-4 <1.45 (no severe fibrosis) (%) 72.9 (69.5–76.0) 86.3 (81.6–89.7) 64.4 (59.7–68.6) <0.001 
 Fib-4 >3.25 (severe fibrosis) (%) 1.3 (0.6–2.3) 0.4 (0.0–1.7) 1.8 (0.9–3.4) 
NAFLD Fibrosis score –0.50 ± 1.30 –0.99 ± 1.32 –0.18 ± 1.18 <0.001 
 NAFLD Fibrosis score <−1.455 (%) 23.5 (20.4–26.6) 36.3 (30.7–42.0) 15.3 (12.1–18.8) 
<0.001 
 NAFLD Fibrosis score >0.676 (%) 17.6 (14.9–20.5) 9.7 (6.6–13.6) 22.6 (18.8–26.6) 
*Chi-square, Fisher’s exact, Mann-Whitney or Student’s t test, as appropriate. 
Data are presented as mean ± SD or as prevalence (95% CI). 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; FLI, fatty liver index; GGT, gamma-
glutamyltransferase; HOMA, homeostasis model assessment; IFG, impaired fasting glucose; IGT, impaired 
glucose tolerance; MET, metabolic equivalents; NAFLD, non-alcoholic fatty liver disease. 
The WBI and the study were approved by the ethical committee of S. Orsola-Malpighi Hospital, 
Bologna, as an interventional, non-pharmacologic study, and patients signed an informed consent 
before entering the program. Comparison with the standard treatment is part of an internal audit to 
test the effectiveness of WBI on specific outcomes. 
Group-based program 
The program has been detailed in previous papers.20,24 Briefly, it consists of group counseling (20–
25 persons) on healthy diet, according to the principles of a Mediterranean diet, and on habitual 
physical activity. It consists of five 120 min weekly sessions, chaired by physicians and dietitians, 
covering: a) energy balance, nutrients and weight monitoring; b) alimentary pyramid and portion 
size; c) food shopping, food labels; d) physical activity, when and how much. The final session is 
chaired by a psychologist and covers the behavioral strategies for stimulus control and weight loss 
maintenance. 
Web-based program 
The web program was developed on a Cloud/SaaS e-learning platform by Docebo SpA (Biassono, 
MB, Italy). It reproduces the group program and is similarly divided into the four sessions detailed 
above, plus a final role-game measuring adherence to previous learning objectives. All sessions 
begin with an introductory message, followed by an online questionnaire to investigate 
consciousness, motivation to change and competence in the specific area. After completing the 
questionnaire, the patients are provided with a series of 25–35 slides per sessions, with texts read by 
a voiceover and figures to support the text. Slides are highly interactive and include examples to be 
completed and games to measure learning objectives. The individual sessions may be repeated 
without limitations, and patients may interact with the clinical center offline, by sending food 
diaries or asking questions via specific tools. The system traced the completion of the program, but 
most interaction occurred via e-mails and was not recorded. 
Study outcomes 
Considering that all individuals were characterized by overweight/obesity, the primary outcome of 
intervention was weight loss. The outcome for analysis was set at 10% weight loss, following the 
evidence that 10% weight loss achieved by intense lifestyle changes improves NAFLD histology.12 
Many secondary outcomes were also tested: a) percentage changes in body mass index (BMI); b) 
return of alanine aminotransferase (ALT) levels within normal values (defined according to the 
updated reference values of ≤31 mU/ml in males and ≤19 in females); c) Changes in dietary intake 
and habitual physical activity (measured at baseline and after six months, to support treatment 
effectiveness); d) changes in surrogate markers of steatosis (FLI score and number of cases with 
FLI <60) and fibrosis (scores of Fib-4 and NFS and fibrosis stage). 
Very few patients were submitted to liver biopsy in the Bologna center; a few more liver biopsies 
were available in individuals referred to Bologna for a second opinion, but follow-up biopsies were 
rarely performed and were not considered as an outcome in the present study. 
Statistical analysis 
A complete database was constructed merging data from the two groups at different time points 
(baseline, and 6-, 12- and 24-month follow-up). All anthropometric data were available; missing 
biochemical and behavioral values (less than 10% for each variable) were imputed using the last-
observation-carried-forward technique. Initially, descriptive statistics were created by computing 
means ± standard deviation for the entire population, as well as for the WBI and GBI cohorts. For 
nominal data, the prevalence and 95% confidence interval (CI) was calculated. Comparison 
between groups was carried out by Student’s t test for unpaired data, chi-square test and Fischer’s 
exact test, as appropriate. Longitudinal changes in clinical data were compared by paired t test and 
repeated ANOVA, considering individuals in active follow-up. Factors associated with primary and 
secondary outcomes (dependent variable) were tested by logistic regression analysis, with type of 
intervention and confounders as independent variables. Given the large difference between the two 
cohort populations, the set of confounders included age, sex, education, employment, baseline BMI 
and the presence of diabetes. ALT at baseline and changes in BMI were also added as confounders 
in the analysis of ALT target reach. 
Results 
Characteristics of the web-treated population 
When compared with individuals enrolled in the standard GBI, WBI individuals were characterized 
by a relative excess of males and younger age (Table 1). Although mean BMI was similar, there 
was a relative, slightly higher proportion of overweight and a lower prevalence of obesity. Blood 
pressure was significantly lower, and the prevalence of diabetes was nearly halved. In addition, they 
had a much higher educational level, and the employment status reflected differences in gender 
prevalence and age (lower prevalence of housewives and retired individuals). 
Biochemistry confirmed lower glucose levels – and lower glycosylated hemoglobin in the presence 
of diabetes – lower liver enzyme and lipid levels. ALT levels were above the updated reference 
values (≥31 in males and ≥20 in females) in 74% of males and 97% of females. 
FLI was above the cut-off for the diagnosis of steatosis in 88% of cases (not different between 
groups), whereas Fib-4 indicated that severe fibrosis was rare, with only one case in WBI vs. 8 in 
GBI (p <0.001). NFS excluded and predicted severe fibrosis in 36% and 10% of WBI cases, 
respectively, vs. 15% and 23% of the GBI cohort (p <0.001). 
The moderately lower severity of liver disease in the WBI group was generally confirmed in the 
very few cases submitted to liver biopsy within six months prior to entering the lifestyle programs 
(Table S1). 
Attrition rates 
In WBI, the number of cases regularly attending control visits decreased progressively to 76%, 58% 
and 43% at 6-, 12- and 24-month follow-up. These figures are lower than those observed in GBI 
(87%, 80% and 69%, respectively; p <0.001). Attrition rates were more common in females, 
irrespective of groups (p <0.001). After adjustment for age, sex, education and employment status, 
severity of obesity and presence of T2DM, both short-term (six-month) and long-term attrition rates 
were significantly associated with WBI (odds ratio (OR) 1.87; 95% CI 1.20–2.90; and OR 2.95; 
95% CI 2.04–4.26, respectively). In both short- and long-term analysis, attrition rates were also 
significantly associated with enzyme levels within normal ranges at baseline (OR 2.39; 95% CI 
1.40–4.07, and OR 1.63; 95% CI 1.01–2.64, respectively), and were reduced in the presence of 
diabetes (OR 0.58; 95% CI 0.36–0.96, and OR 0.46; 95% CI 0.32–0.67). 
Lifestyle changes 
At baseline the dietary intake was not different in the two cohorts, but WBI individuals derived a 
moderately higher amount of calories from carbohydrates and a lower amount from lipids (Table 2). 
The amount of physical activity was generally low, but higher in the WBI cohort. 
Table 2. Lifestyle habits at baseline (last one week) and after six months, according to treatment 
groups (mean ± SD). 
Variable Baseline 6 months 
 Web–treated 
n = 211 
Group–
treated 
n = 383 
p 
value 
Web–treated 
n = 160 
Group–
treated 
n = 352 
p 
value 
Calorie intake 
(kcal/day) 2,066 ± 455 2,028 ± 327 0.189 1,801 ± 272 1,833 ± 265 0.174 
 Carbohydrate 
content (%) 49.8 ± 7.1 48.7 ± 6.8 0.030 – – – 
 Protein content 
(%) 15.6 ± 2.8 15.2 ± 2.7 0.057 – – – 
 Lipid content (%) 34.4 ± 6.3 36.1 ± 6.2 <0.001 – – – 
Physical activity 
(MET/h/wk) 19.5 ± 14.8 15.5 ± 14.4 <0.001 28.6 ± 13.8 23.2 ± 15.7 <0.001 
*Significantly different from the corresponding value in group-treated cases (chi-square, Fisher’s exact, 
Mann-Whitney or Student’s t test, as appropriate). 
After six months, calorie intake significantly decreased in the two cohorts, more markedly in WBI 
(WBI, −273 ± SE 31 kcal/day; GBI, −193 ± 13 in GBI; p = 0.006, paired t test), whereas physical 
activity significantly increased from baseline, without differences between groups (WBI, +9.5 ± SE 
1.0 MET/hour/week; GBI, +8.1 ± 0.6; p = 0.183) (Table 2). 
Primary weight loss outcome 
In patients compliant to follow-up, BMI decreased progressively in both treatment arms by nearly 
two points, without differences between groups (time x treatment ANOVA, p = 0.063). In the WBI 
cohort, body weight decreased on average by 3.4% at 6 months, by 4.9% at 12 months and 5.5% at 
12 months (all p <0.001, paired t test) in the per protocol analysis, and similarly by 3.1%, 4.0% and 
4.2% in the GBI cohort (Fig. 1 and Table 3). 
 
 
Fig. 1. Percentage weight loss in patients with NAFLD enrolled in the web-based (grey circles) and the 
group-based (white circles) lifestyle intervention programs. The number of cases achieving the 10% weight 
loss target at different time points is reported in the Table. Note that no differences between groups were 
demonstrated at any time point. NAFLD, non-alcoholic fatty liver disease. 
Table 3. Weight loss and changes in biochemistry in NAFLD, according to treatment group 
(mean ± SE). 
Variable 6 months 12 months 24 months 
 
Web–
treated 
n = 211 
Group–
treated 
n = 383 
Web–
treated 
n = 160 
Group–
treated 
n = 352 
Web–
treated 
n = 118 
Group–
treated 
n = 301 
Δ Body weight 
(%) −3.4 ± 0.2
* −3.1 ± 0.2 −4.9 ± 0.4* −4.0 ± 0.3 −5.5 ± 0.5* −4.2 ± 0.3 
 Weight loss 
>5% (%) 21.3 20.1 28.1 23.9 23.7 25.6 
 Weight loss 
>10% (%) 5.2 7.3 13.1 10.8 20.4 14.6 
Δ WC (cm) −3.4 ± 0.3* −2.6 ± 0.2 −4.9 ± 0.6* −3.2 ± 0.3 −5.8 ± 0.6* −3.8 ± 0.4 
Δ ALT (U/L) −14.3 ± 1.4 −17.1 ± 1.3 −18.5 ± 2.4 −18.5 ± 1.6 −22.0 ± 3.0 −19.4 ± 1.8 
ALT 
Normalization 
(%) 
18.1* 7.1 32.5* 13.9 34.7* 19.9 
 Normal ALT 
(%) 31.8
* 16.7 43.1* 22.4 45.8* 28.9 
Δ GGT (U/L) −7.4 ± 2.2* −12.6 ± 1.7 −16.4 ± 5.2 −15.2 ± 2.0 −23.5 ± 6.9* −16.1 ± 2.2 
Δ TG (mg/dl) −15.6 ± 5.6 −23.5 ± 4.0 −24.9 ± 7.8 −27.9 ± 7.9 −23.4 ± 9.8 −26.6 ± 5.1 
Δ BG (mg/dl) −4.3 ± 1.2 −7.9 ± 1.3 −5.9 ± 1.6 −9.6 ± 1.4 −5.7 ± 1.8 −9.0 ± 1.8 
The percentage of cases who reached the desired 10% weight loss and ALT levels within the 
updated reference values is also reported (%). The total percentage of cases with normal ALT at 
each time point is also given. 
ALT, alanine aminotransferase; BG, blood glucose; GGT, gamma-glutamyltransferase; TG, 
triglycerides; WC, waist circumference. 
* 
Significantly different from the corresponding value in Group-treated cases (chi-square, 
Fisher’s exact, Mann-Whitney or Student’s t test, as appropriate). 
Weight loss >10% initial body weight was registered in 5%, 13% and 20% of cases in WBI at 6-, 
12- and 24-month follow-up, and in 7%, 11% and 15% in GBI (all, p not significant). Another 20–
28% of cases attained a weight loss >5% of initial body weight at different time points (Table 3). 
Weight cycling was not common; only 14 patients in GBI and 2 in WBI who had attained the 10% 
weight loss at 6- or 12-month follow-up regained weight and were no longer at target after two 
years (Fisher’s exact test, p = 0.166) (Table 3). 
Secondary outcomes 
Changes in ALT levels and return within normal values 
All liver enzymes decreased significantly in the course of the observation period, irrespective of 
treatment group (Fig. 2). This was mainly the case of ALT levels that declined on average by 
22 ± SD 32 mU/ml in the two-year follow-up (Table 3). 
 
Fig. 2. Time course of ALT levels in patients with NAFLD enrolled in the web-based (grey circles) and 
the group-based (white circles) lifestyle intervention programs. In the Table, the numerator gives the 
number of cases with ALT decreased within normal range following treatment (the total number with normal 
ALT is in brackets), the denominator is the total number of cases, with the total percentage with normal ALT 
at different time points in square brackets. ALT, alanine aminotransferase; NAFLD, non-alcoholic fatty liver 
disease. 
Overall, a higher number of cases had normal ALT levels in the course of follow-up. Among 
individuals with altered ALT levels at baseline, ALT normalized in 18% of cases after 6 months, in 
32% at 12-month and 35% at 24-month follow-up in the WBI cohort. The corresponding values in 
the GBI group were 16% (vs. WBI, p <0.001), 22% (vs. WBI, p <0.001), and 29% (vs. WBI, 
p = 0.002) (Table 3). 
Changes in surrogate markers of steatosis 
The score of FLI decreased significantly in the course of the observation period in both groups (Fig. 
3), more markedly in the WBI cohort after one (71.3 ± 20.9 vs. 78.0 ± 17.9 in GBI; p <0.001) and 
two years (68.9 ± 23.2 vs. 76.3 ± 19.2; p = 0.002). At 24 months FLI excluded steatosis (FLI <30) in 
7% of WBI cases, 26% were classified as indeterminate (30<FLI<60), and steatosis was still 
diagnosed only in 67% of cases. The corresponding figures in GBI group were 3%, 19% and 78% 
(p = 0.053). 
 
Fig. 3. Box plot representation of the time course of surrogate markers of steatosis and fibrosis in individuals 
enrolled in the group-based (white boxes) and web-based (grey boxes) lifestyle intervention programs. For 
all surrogate markers, ANOVA reveals significant differences between treatment categories (p <0.001). 
Changes in Fib-4 and NAFLD fibrosis score 
Both Fib-4 and NFS marginally decreased in the course of follow-up, and changes were significant 
for Fib-4 in both groups (Fig. 3). Severe fibrosis was no longer diagnosed by Fib-4 in four out of 
five cases available at follow-up in the control group, whereas no changes were observed in the web 
cohort. No significant changes in fibrosis score and stage were demonstrated by NFS. 
Association of treatment and target reach 
In logistic regression analysis, 10% weight loss after two years was only associated with baseline 
BMI (OR 1.43; 95% CI 1.13–1.81 per BMI/5). After adjustment for confounders (age, sex, 
education, employment, presence of diabetes, baseline BMI), the participation in WBI program did 
not significantly reduce the possibility of reaching the predefined weight loss target in comparison 
to GBI (Fig. 4). Additionally, assuming that all cases missed at follow-up did not attain the 10% 
weight loss at two years, this outcome was reached by intention-to-treat in 8.6% in WBI and 10.0% 
in GBI (p = 0.601), and participation in GBI did not reduce the probability of reaching the fully 
adjusted long-term 10% weight loss (OR 0.70; 95% CI 0.38–1.27). 
 
Fig. 4. Association of web-based lifestyle intervention with weight loss ≥10% initial body weight and ALT 
levels within normal values, compared with group-based lifestyle intervention, at 12-month (closed squares) 
and 24-month follow-up (closed circles). *Adjusted for age, sex, education, employment status, baseline 
BMI and ALT, and the presence of T2DM. ^Adjusted as above + weight change from baseline. ALT, alanine 
aminotransferase; BMI, body mass index; T2DM, type 2 diabetes mellitus. 
WBI increased the rate of ALT normalization non-significantly at 6 months (OR 1.65; 95% CI 
0.82–3.30), and significantly at 12 months (OR 2.58; 95% CI 1.41–4.71) and 24 months (OR 2.21; 
95% CI 1.17–4.15), after adjustment for age, gender, education level, employment status, BMI and 
ALT at baseline, BMI changes at different time points, and the presence of T2DM (Fig. 4). 
Additional adjustment for calorie intake and physical activity at baseline did not change the results. 
Discussion 
The study demonstrates that web-based education is able to produce beneficial effects in patients 
with NAFLD, similar to those that can be obtained by group education. Although a higher number 
of cases were lost to follow-up in the web program, the total number who achieved the desired 10% 
weight loss target on intention-to-treat was similar, and it was also similar to the number who 
attained the same target in the Cuban experience.12 This target was specifically chosen considering 
that it was associated with nearly universal NASH resolution at one-year follow-up liver biopsy, 
with improvement in steatosis, lobular inflammation and ballooning, and with stabilized or 
regressed fibrosis.12 Notably, in our study the 10% weight loss was maintained at two years, 
accompanied by stable or improved surrogate markers of steatosis and fibrosis. 
The use of web education in the management of non-communicable diseases has long been 
suggested, considering the huge number of cases at risk and patients’ needs. The majority of cases 
are in an age range where job constraints make it difficult to implement a systematic face-to-face or 
group approach, whereas the eHealth procedures may keep the contact between patients and 
therapists without disrupting normal daily living. 
The number of internet-based approaches for lifestyle changes in self-management programs has 
increased in several settings, both in adolescents and in adults,25-27 and in different non-
communicable diseases.28-32 The most recent approaches allow for interaction with therapists, and 
also with peers in discrete groups, while maintaining privacy. Accordingly, they tend to overcome 
the drawbacks of classical approaches, based on face-to-face or group-based meetings with 
counselors, reaching the limited audience able to attend the clinic during working hours, in 
countries where treatment is regulated by a universal healthcare system, or are able to pay for 
private treatment. 
In general, internet-based programs were shown to be less effective than face-to-face programs; 
their effectiveness may be increased by telephone recall systems33 or text messages34 but the 
reduced effectiveness is largely repaid by reduced costs and a larger audience.35 This was also 
demonstrated in our setting, where nearly 60% of cases engaged in WBI lived outside the 
metropolitan area (and a few were scattered all over Italy), compared with the 27% of cases who 
entered the group-based behavioral approach. 
The critical point in behavioral programs is engagement. Whenever Internet programs are used 
without any structured motivational approach, the results are expected to be poor. For this reason, 
the entry in our web program was regulated with the very same rules of access to the GBI program, 
i.e. the strategies of motivational interviewing according to Miller and Rollnick.16 This strategy is 
the basis to achieve a significant adherence to the program36 and has been successfully incorporated 
into behavioral programs aimed at healthy diet and habitual physical activity for weight loss in 
several diseases.37-40 Patients were provided the user-id and password to access the system 
following a structured face-to-face meeting, and motivation to change was tested by appropriate, 
validated tests.14 Reinforcements were provided during follow-up visits, in a similar way 
irrespective of treatment group. 
Attrition was large in our population, and larger in the web-based cohort. A post hoc analysis of 
attrition rates showed that it was similar between those living within and outside the metropolitan 
area of Bologna (58% and 59%, respectively). Attrition remains a critical issue in the treatment of 
non-communicable diseases, where patients’ behavior is pivotal to achieving favorable outcomes. 
Very high attrition rates (up to 50%) are also reported in recent industry-sponsored randomized 
controlled trials (RCTs) of pharmacological treatment of obesity.41-43 where retention may be 
enhanced by the possibility of having treatment for free. The two-year follow-up rate measured in 
the present setting was much lower than usually found in the real world of obesity treatment,44 
where drop-out was not systematically associated with treatment failure.45 In addition, attrition rates 
were associated with the presence of normal liver enzymes, in line with patients’ belief that normal 
enzymes exclude progressive disease. Unfortunately, any additional contact with drop-outs is now 
precluded by Italian regulation on privacy, and no inference can be made on data in individuals 
missed at follow-up. 
Both GBI and WBI interventions were effective in modifying dietary intake and physical activity, 
as demonstrated at six-month follow-up. Changes in calorie intake (approximately 200 kcal/day) are 
in agreement with the resulting two-year weight loss, and the negative energy balance was enlarged 
by small, but significant increases in physical activity in patients enrolled in WBI. Differences 
between cohorts are probably the result of differences in age and gender composition, which might 
also produce a different compliance to calorie restriction and physical activity, and should not be 
taken as proof of superiority of WBI vs. GBI. These differences should however be considered 
when planning lifestyle programs in free-living individuals with NAFLD. 
Weight loss was accompanied by a remarkable reduction in liver enzymes, as well as stability or 
improvement in surrogate markers of steatosis and fibrosis. NASH and disease progression may 
also be present in individuals with normal aminotransferase levels,46 but histological improvement 
is consistently associated with decreased aminotransferase, also in individuals with levels within the 
normal range at baseline. Normalization in the web-based cohort was not less common than 
observed in the group cohort, confirming that web education was at least as effective as the 
traditional approach. This conclusion is largely supported by the longitudinal analysis of surrogate 
markers, confirming a progressive reduction of steatosis with no worsening or improvement of 
fibrosis in individuals attending follow-up, without significant differences between cohorts. 
The study has both strengths and limitations, which must be adequately discussed. The strengths are 
the novelty of the behavioral approach in this setting, the very large sample size, and a follow-up 
longer than that reported in randomized studies of behavioral treatment. Limitations are inherent in 
the observational nature of the study, with a control group reflecting the standard of care in 
NAFLD, as derived from clinical practice guidelines.6 
Firstly, the general population might be partly different from the one usually tested in NAFLD 
RCTs. Individuals were recruited inside a unit serving as a specialist unit for NAFLD, but also 
caring a general population with obesity and diabetes. Accordingly, the BMI of patients might have 
been higher than usually observed in liver units, and the prevalence of T2DM might have been 
larger. However, in the most recent large RCTs published the mean BMI and the prevalence of 
T2DM were 35 kg/m2 and 53% (obeticholic acid, FLINT study),47 31 kg/m2 and <40% (elafibranor, 
GOLDEN-505 study)48 and 34 kg/m2 and 50% (cenicriviroc, CENTAUR study),49 respectively. 
Accordingly, differences exist when compared with the NAFLD population principally enrolled in 
the U.S., but our cohort appears to be truly representative of the European NAFLD population. 
Notably, the population is very similar to that treated by lifestyle modifications in the behavioral 
intervention trial of Vilar-Gomez et al.12 
Secondly, the population is scarcely defined by histology, and the effects of treatment are 
exclusively based on surrogate markers. Liver biopsy at baseline was available in less than 10% of 
cases, more commonly in patients entering the web-based cohort to be observed for a second 
opinion after being diagnosed in other centers. Liver disease was generally not severe, with a very 
limited proportion of cases with F3-4 fibrosis, and no statistically significant changes were 
expected. The number of cases who achieved the weight loss target able to promote fibrosis 
regression was similar to that observed in the Cuban intervention, where only 11% of cases had 
fibrosis F3.12 This suggests that the effectiveness of WBI, also in terms of histologic targets, might 
be comparable to that reported in the Cuban experience, but this remains to be demonstrated. 
Unfortunately, transient elastography was rarely performed (more commonly, in the web cohort and 
outside our institution, where it was not available when the project started), and the number of cases 
available at follow-up was insufficient for any analysis. Surrogate imaging techniques, now largely 
available in research hospitals might be used to confirm these beneficial effects. 
Finally, the population enrolled into the internet program differed from the GBI population for a 
few, but important characteristics, including diabetes prevalence and visceral obesity. Although the 
association with target reach was tested after adjustment for confounders, the possibility remains 
that other features, not tested in the analysis, might have produced a confounding effect. 
Differences in age, education and job placement might have generated a stronger motivation to 
lifestyle changes not documented in the comparison with the GBI cohort. We would like to remark 
that the intent of including a GBI cohort in the report was not to demonstrate any superiority of a 
specific treatment approach, but merely to report the benchmark of the standard lifestyle approach 
used to derive WBI. Validation by properly designed randomized studies is needed for a proper 
comparison of the different lifestyle interventions. 
In conclusion, this observational study indicates that an internet-based cognitive and educational 
program may be used to deliver multiple-session education to motivated patients with NAFLD who 
cannot attend face-to-face or group-based procedures. This approach produces beneficial behavioral 
changes, similar to those observed with the intensive lifestyle interventions carried out by trained 
teams, when added to motivational interviewing and counseling in a specific population, younger, 
less sick, technologically smart, maintained on a pre-programmed outpatient visit schedule. The 
WBI program might be extended to other units and/or general practitioners, increasing its impact in 
the community in prevention and treatment of progressive NAFLD. It might also be superimposed 
to drug treatment in the most severe cases, with possible additive effects. A likely opportunity is 
adding intensive lifestyle treatment to glucose-lowering therapy with glucagon-like peptide-1 
receptor agonists, under investigation following pilot studies with positive results in NAFLD, at 
least in the population with prediabetes/diabetes.50 Considering the burden of NAFLD in the 
community,4 any large-scale strategy should be tested to reduce the burden of disease on patients 
and on healthcare systems. 
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